GBA's "2021 Stock Phantasma"
- Thread starter stonedinvestor
- Start date
funny scene at the beach. Brother-in-law stock broker comes to where we are sitting. He is freaking out about the market and selling a lot of energy names. The lead chart guy at his firm is seeing red flags (who isn't). After he is done calling in a bunch of sells, I pitch him on XAIR and he bought it on the spot!
PT - $33 I think! At lest $30
I owe Verizon $200 so far using this hot spot.
Chewie also being bought out here, it seems that's a more popular HF trade than I thought.
I find it very hard to come up with ideas at the beach.
Things I re remembered about the beach.
- the water is super cold this time of year
-and kind of dirty
-girls wear thongs at an increasingly young age
-cocaine makes it tough to sleep
-it's ten degrees cooler here than the city
-which is good because the city is 98
Chewie also being bought out here, it seems that's a more popular HF trade than I thought.
I find it very hard to come up with ideas at the beach.
Things I re remembered about the beach.
- the water is super cold this time of year
-and kind of dirty
-girls wear thongs at an increasingly young age
-cocaine makes it tough to sleep
-it's ten degrees cooler here than the city
-which is good because the city is 98
van your post caught my eye because her bio is really impressive. rockefeller, sloan kettering. she looks like she's 23. i'm going to try to read her stuff.I thought that was a joke. I guess not.
https://www.chardan.com/Geulah-Livshits
I say we listen to whatever she has to say Stoney.
You know she's been teased all her life for that name.
I bet she's the smartest biotech analyst out there.
Two thumbs-up.
What are her other picks?
I want an obscure one.
___________________________
Prior to joining Chardan, Dr. Livshits was a Postdoctoral Research Fellow in the laboratory of Dr. Scott Lowe at Memorial Sloan Kettering Cancer Center, where she developed CRISPR and RNAi approaches to study pancreatic cancer in vivo and in organoid models. Dr. Livshits conducted her thesis research in the laboratory of Dr. Elaine Fuchs at The Rockefeller University, where she studied mechanisms of skin development and regeneration. Her doctoral and postdoctoral work has been published in peer-reviewed academic journals including Nature, Nature Medicine, Nature Biotechnology, eLife, PNAS, and Human Gene Therapy.
Dr. Livshits received her BS from Brandeis University, her PhD from The Rockefeller University, and was a Postdoctoral Research Fellow at Memorial Sloan Kettering Cancer Center.
NTLA
Intellia Therapeutics Inc
133.43 USD+44.60 (50.21%)today
Why?
You can't log on to Seeking Alpha?
Btw...
By this time tomorrow, we'll have 100K views Stoney.
Even @Buy1Sell2 's ES journal can't top that.
...You're welcome.
Last edited:
our girl livshits has PT at $51.
Send her an invite to join ET.
I'll buy whatever she recommends.
Cathie would do well to steal her away.
I've noticed that when Bloomberg has a talking head in from the female side it's been this other lady not Cathie, that had to really tick Cathie off.
FTA awards low or no emission program grants to procure Proterra services 08:09 PTRA Proterra announced that 10 transit agencies have been awarded Federal Transit Administration, FTA, Low or No Emission Program Grants, Low-No, to procure Proterra electric transit buses, charging infrastructure, and Proterra Powered low-floor shuttles in partnership with Optimal Electric Vehicles. It marks the sixth consecutive year under the Fixing America's Surface Transportation, FAST, Act that the FTA has awarded transit agencies Low-No grants to procure Proterra buses and charging systems.
FTA awards low or no emission program grants to procure Proterra services 08:09 PTRA Proterra announced that 10 transit agencies have been awarded Federal Transit Administration, FTA, Low or No Emission Program Grants, Low-No, to procure Proterra electric transit buses, charging infrastructure, and Proterra Powered low-floor shuttles in partnership with Optimal Electric Vehicles. It marks the sixth consecutive year under the Fixing America's Surface Transportation, FAST, Act that the FTA has awarded transit agencies Low-No grants to procure Proterra buses and charging systems.